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Background: The efﬁcacy of Tyrosine Kinake inhibitors (TKIs) of 
EGFR is associated with well characterized mutations on the exons 18, 
19 and 21 of EGFR gene. Less common mutations could be detected in 
these exons but their relationship with the clinical efﬁcacy of TKIs has 
not been established yet. 
Methods: Genomic DNA was extracted from microdissected formalin-
ﬁxed parafﬁn-embeded tumor tissue from 86 pts enrolled in a geﬁtinib 
expanded access program. Exons 18, 19 and 21 were ampliﬁed and 
subjected to direct sequencing. 
Results: Classical EGFR mutations (CM) were detected in 9 (10.4%) 
pts and other mutations variants (MV) in 19 (22%) pts. Eight (42.1%) 
MV were observed in exon 18, 3 (15.8%) in exon 19 and 8 (42.1%) 
in exon 21. Tumor Growth Control (TGC) was achieved in 88.9% 
(3PR and 5SD) pts with CM, 63% (2PR and 10SD) pts with MV and 
in 45.9% (3PR and 25SD) pts with wild type EGFR gene (WT). There 
was no clear association between the presence of EGFR MV and the 
sex, histology or smoking history. The median TTP was 64 weeks 
(range:4-80+), 20 weeks (range:6-140) and 16 weeks (range:4-176+) 
in pts with CM, MV and WT, respectively. Nine (47.3%) pts with 
EGFR MV had a TTP >24 weeks. The median survival was 78 weeks 
(range:5-94+), 70 weeks (range:10-142) and 36 weeks (range:4-176+) 
in pts with CM, MV and WT, respectively. Three patients bearing 
mutations in exons 18, 19, and 21 progressed despite geﬁtinib treat-
ment suggesting that these mutations could be related to resistance to 
geﬁtinib. 
Conclusions: EGFR mutation variants could be associated with 
response or resistance to TKIs but their low incidence requires their 
evaluation in a largest cohort of patients. 
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Background: Surgery improved the results of treatment for stage IIIA 
non small cell lung cancer (NSCLC). However, a signiﬁcant fraction 
of patients after surgical resection die due to local or systemic re-
lapses. Nonetheless, the best adjuvant therapy to improve survival and 
decrease relapse rate remains as an ever controversial issue. There-
fore, we conducted a randomized trial to determine whether or which 
postoperative adjuvant therapy is beneﬁcial in prolonging survival and 
decreasing recurrence in patients with completely resected stage IIIA 
NSCLC. 
Methods: This trial was initiated by the Lung Cancer Research Team 
at Korea Cancer Center Hospital March 1989, and enrollment was 
stopped December 1998. It was designed as a randomized, prospec-
tive three-armed study with surgery only (control group, 55 patients) 
versus surgery plus adjuvant radiotherapy (study group I, 56 patients) 
and surgery plus adjuvant MVP (mitomycin C, vinblastin and cisplatin) 
chemotherapy (study group II, 53 patients). 
Results: Data for all the patients were complete after long-term follow-
up. Thirty-eight patients in the control group, thirty patients in the study 
group I and twenty-nine patients in the study group II experienced 
tumor recurrence during follow-up. The median times of disease-free 
were 16.3 months (control group), 35.3 months (study group I), and 
36.6 months (study group II). The 5-year disease-free survival rates 
were 28.9%, 41.1% and 49.4%, respectively (p=0.10, log-rank test). 
Even though there was no signiﬁcant difference statistically, log-rank 
test for trend of disease-free survival was signiﬁcant (p=0.039). Only 
twelve patients (control group), nine patients (study group I), and 
sixteen patients (study group II) were survived until the end of follow-
up. The median survival times were 31.8 months (control group), 27.0 
months (study group I), and 55.7 months (study group II). The 5-year 
overall survival rates were 29.8 %, 37.5% and 48.1 %, respectively 
(p=0.22, log-rank test).
Conclusions: Our results suggest that the addition of adjuvant radio-
therapy or adjuvant MVP chemotherapy may not reduce the incidence 
of recurrence and prolong the disease-free or overall survival rates of 
the patients with stage IIIA NSCLC after surgery.
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Aim: Retrospective analysis of treatment with cisplatin/gemcitabine 
followed by cisplatin/etoposide and concurrent thoracic radiotherapy 
(TRT) for patients with irresectable or medically inoperable non-small-
cell lung cancer (NSCLC).
Methods: Stage III NSCLC patients received one course of cisplatin 
(80mg/m2, day 1) and gemcitabine (1250mg/m2, day 1 and 8) followed 
by cisplatin (80mg/m2, day 21 and 42) and etoposide (100mg/m2, days 
21-23 and 42-44). Concurrent TRT commenced on day 22, 5 days/week 
for 5 weeks. National Cancer Institute of Canada grading system v3.0 
was used for evaluation of toxicity. Radiological response was evalu-
ated using RECIST criteria. Patients with potentially resectable stage 
III NSCLC and good performance status underwent mediastinal restag-
ing after 46-50 Gy followed by surgery if no N2-disease or distant 
metastatic disease was found. All others received radiotherapy to a total 
dose of 50-60 Gy.
Results: A total of 57 patients were treated between October 2003 and 
December 2006. Of those, 5 had medically inoperable stage IIA (1) 
and IIB (4), 24 stage IIIA, 25 stage IIIB and 3 patients with stage IV 
NSCLC. Prior treatments for NSCLC in 14 patients included pneu-
monectomy (3), (bi)lobectomy (9), stereotactic radiotherapy (1) and 
chemotherapy (6). During 178 evaluable courses of chemotherapy 
(total 179 courses), grade III/IV anemia was reported in 6 courses 
(3.4%), grade III/IV thrombocytopenia in 22 courses (12.4%) and grade 
III/IV leucocytopenia in 65 courses (36.5%). One patient died of grade 
V febrile neutropenia and one patient died as a result of lung bleeding 
after 6 Gy. Transfusions for anemia were necessary after 12 courses and 
hospitalisation for neutropenic fever in 7 cases. Carboplatin replaced 
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cisplatin in 5 patients (14 courses), mainly due to nephrotoxicity. Three 
patients developed pulmonary embolism during treatment. Overall 
median total dose for radiotherapy was 55 Gy (range 6-60), patients eli-
gible for surgery received a median total dose of 48 Gy (range 46-60). 
Percentage of normal lung volume receiving 20 Gy (V20) ranged from 
0 - 44.6%. Esophagitis >grade I was observed in 35 patients (61.4%): 
Grade II (n=22) and grade III (n=13). Two patients were not evaluable 
for radiological response. Forty-one patients had a partial response, 9 
stable disease and 5 progressive disease. Objective response rate (ORR) 
is therefore 74.5% (95% CI: 61.6 - 84.3%). Nineteen patients (15 
stage III) underwent a (radical) resection after restaging, and 7 of these 
had a complete pathological remission (cPR). All cPR patients had a 
radiological partial response. After a median follow up of 10 months, 
38 patients (66.7%) are alive. Local recurrence of NSCLC occurred in 
9 patients, 6 developed distant metastatic disease, of whom 4 had brain 
metastases.
Conclusion: Chemoradiotherapy with cisplatin/gemcitabine followed 
by cisplatin/etoposide and concurrent thoracic radiotherapy for ir-
resectable or medically inoperable NSCLC patients is relatively well 
tolerated and shows a high objective response rate.
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Background: The most satisfactory treatment for patients with locally 
advanced NSCLC is combination chemotherapy-radiotherapy (CT-RT). 
However, the optimal interval between irradiation and chemotherapy as 
well as the most effective chemotherapy protocol remains to be deﬁned.
Our aim was to conduct a multicenter phase II trial of the cisplatin-oral 
vinorelbine -radiotherapy combination after induction chemotherapy 
with cisplatin-docetaxel in patient with NSCLC. Vinorelbine is effec-
tive as the intravenous form in concomitance with RT for the treatment 
of NSCLC and oral form may reduce some disagreements provoked by 
intravenous injections: stress, infections, hemorrhage, displacement at 
the hospital and cost of CT. 
Method: Patients (pts) with histologically or cytologically conﬁrmed 
unresected stage IIIA and IIIB NSCLC previously untreated, PS ≤ 1, 
and weight loss ≤ 10 % received two cycles of induction CT cisplatin 
(75 mg/m2) and docetaxel (75mg/m2) days 1 and 22. Pts with response 
or stable disease continued with thoracic radiotherapy (2 Gy/day, 5 
days/week, total dose of 66 Gy, beginning day 57) concomitant with 2 
cycles of cisplatin (80mg/m2) (days 57 and 78) and oral vinorelbine (40 
mg/m2) (days 57, 64, 78 and 85). The interim analysis was planned on 
the ﬁrst 15 evaluated pts for response and toxicity (pts who received the 
2 sequences of treatment: induction CT and concomitant CT-RT). The 
enrollment of pts continued if more than 4 objective responses and less 
than 4 grade III-IV pulmonary or esophagus toxicity were observed. 
Results: Twenty two pts were enrolled to obtain 15 evaluated pts. 
Seven pts did not receive the concomitant CT-RT because of the fol-
lowing reasons: 3 pts presented progression disease after induction CT, 
1 died due to concomitant disease, 1 stopped treatment due to toxicity 
(pneumopathy), 2 pts were withdrawn from study because of protocol 
deviation. The characteristics of the 15 evaluated pts are: mean age 
57 (46-69), 10 males, PS 0/1 9/6 pts, stage IIIA/IIIB 5/10 pts, histol-
ogy squamous cell carcinoma/adenocarcinoma/large cell 3/8/4 pts. 
All these pts received the intended treatment. No complete response 
was observed neither after induction CT nor after concomitant CT-RT. 
Response rate to induction CT was 40% (95%CI: 15-65) (6 pts) and 
to concomitant CT-RT 80% (95%CI: 60-100) (12 pts). The overall 
response rate in ITT was 54.5% (95%CI: 33-75). One patient presented 
progression disease after concomitant CT-RT (this patient has a stable 
disease after induction CT). Median survival was not reached. Seven 
pts experienced severe toxicities after concomitant CT-RT: esophagitis 
grade III (1 pt), esophagitis grade IV (1 pt), severe neutropenia (4 pts) 
and bronchial infection (1 pt). No pulmonary toxicity and treatment 
related death occurred. 
Conclusions: The result of the interim analysis demonstrated that the 
tested combined treatment modality is feasible and well tolerated by 
the patients. This result allows us to continue patients enrollment on the 
study. The total number of patient needed is 30 evaluated pts which we 
expect to reach when 60 patients will be enrolled. Further results will 
be given at the time of the abstract presentation.
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Background and Purpose: Evidence supports concurrent chemo-
radiotherapy as an option in the treatment of locally advanced stage 
III NSCLC. We present the long term results of a prospective phase 
II study aimed to determine the response rate (RR), toxicity, time to 
progression (TTP) and survival (S) of concurrent Vinorelbine (Vrb) and 
Cisplatin (Cis) or Carboplatin ( Carbo), with radiotherapy (RT), fol-
lowed by consolidation ChT with the same drugs, for stage III NSCLC. 
In order to decrease toxicity the role of protectors like amifostine has 
been evaluated.
Methods and Materials: 58 eligible pts were included the study from 
16.11.2000 to 18.09.2003. Pts characteristics were: median age 59 
(44-71), M/F=50/8, PS 1/2=28/30, stage IIIA/IIIB=11/47, squamous 
cell cc 45, adenocc 7, adenoid chistic cc 1, large cell cc 5. Treatment 
consisted of 2 cycles of ChT with Vrb (15 mg/sqm, d 1, 8, q21) and Cis 
(80 mg/sqm, d 1, q 21) or Carbo (AUC 2.5) given concurrently with 
RT (56-60 Gy/ 28-30 fractions/5.5- 6 weeks), followed by 2-4 cycles of 
consolidation ChT with the same drugs (Vrb 25 mg/sqm d 1,8, Cis 100 
mg/sqm, or Carbo AUC 5 d1, q 21). 22 pts received Amifostine 740 
mg/sqm, d1, 8, q 21, given intravenously. At least 4 cycles of ChT have 
been completed by 64% and optimal doses of RT by 79% of pts.
Results: 58 pts were evaluable for toxicity. Severe grade 3 or 4 toxici-
ties were: neutropenia in 11(19%) pts, esophagitis in 11(19%) pts, 
